CTIS2023-508638-32-00进行中（未招募）1 期
Intermittent ibrutinib in chronic lymphocytic leukemia
Karolinska University Hospital0 个研究点目标入组 50 人开始时间: 2023年10月9日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
2 期
Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)Malignant Neoplasms Stated as Primary Lymphoid HaematopoieticSmall Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNCT03207555M.D. Anderson Cancer Center23
已完成
1 期
Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With IbrutinibLeukemia, Lymphocytic, Chronic, B-CellNCT02759016Boehringer Ingelheim7
已完成
2 期
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic LeukemiaB-Cell Chronic Lymphocytic LeukemiaB-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis)NCT03755947Grupo Cooperativo de Hemopatías Malignas3
Unknown
3 期
Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus CarriersIndolent B-cell LymphomasChronic Hepatitis BLymphoma, Small LymphocyticMantle-Cell LymphomaWaldenstrom's MacroglobulinaemiaChronic Lymphocytic LeukemiaFollicular LymphomaNCT02991638The University of Hong Kong62
已完成
2 期
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaB-Cell Chronic Lymphocytic LeukemiaB-Lymphocytic Leukemia, ChronicLeukemia, Chronic LymphaticLeukemia, Chronic Lymphocytic, B-CellLeukemia, Lymphocytic, ChronicLeukemia, Lymphocytic, Chronic, B-CellLymphocytic Leukemia, Chronic, B CellLymphocytic Leukemia, Chronic, B-CellChronic Lymphocytic LeukemiaNCT03204188National Heart, Lung, and Blood Institute (NHLBI)15